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Introduction: The mutational profile of non–small-cell lung can-
cer (NSCLC) has become an important tool in tailoring therapy to 
patients, with clear differences according to the population of ori-
gin. African Americans (AAs) have higher lung cancer incidence and 
mortality than Caucasians, yet discrepant results have been reported 
regarding the frequency of somatic driver mutations. We hypoth-
esized that NSCLC has a distinct mutational profile in this group.
Methods: We collected NSCLC samples resected from self-reported 
AAs in five sites from Tennessee, Michigan, and Ohio. Gene mutations 
were assessed by either SNaPshot or next generation sequencing, and 
ALK translocations were evaluated by fluorescence in situ hybridization.
Results: Two hundred sixty patients were included, mostly males 
(62.3%) and smokers (86.6%). Eighty-one samples (31.2%) were 
squamous cell carcinomas. The most frequently mutated genes were 
KRAS (15.4%), epidermal growth factor receptor (EGFR, 5.0%), 
PIK3CA (0.8%), BRAF, NRAS, ERBB2, and AKT1 (0.4% each). ALK 
translocations were detected in two nonsquamous tumors (1.7%), 
totaling 61 cases (23.5%) with driver oncogenic alterations. Among 
179 nonsquamous samples, 54 (30.2%) presented a driver altera-
tion. The frequency of driver alterations altogether was lower than 
that reported in Caucasians, whereas no difference was detected in 
either EGFR or KRAS mutations. Overall survival was longer among 
patients with EGFR mutations.
Conclusions: We demonstrated that NSCLC from AAs has a differ-
ent pattern of somatic driver mutations than from Caucasians. The 
majority of driver alterations in this group are yet to be described, 
which will require more comprehensive panels and assessment of 
noncanonical alterations.
Key Words: Lung neoplasms, Mutations, EGFR, African Americans, 
Ethnic groups.
(J Thorac Oncol. 2015;10: 1430–1436)
The mutational profile of non–small-cell lung cancer (NSCLC) has become an important tool in tailoring ther-
apy to patients.1 Currently, several somatic mutations or rear-
rangements can be successfully targeted with specific agents 
such as tyrosine kinase inhibitors of the epidermal growth fac-
tor receptor (EGFR) and anaplastic lymphoma kinase (ALK) 
inhibitors.2,3
The prevalence of classic driver mutations may vary 
according to clinical and tumor characteristics—age, gender, 
smoking status, and histology—and has been thoroughly stud-
ied in large populations around the world.2,4–6 For instance, 
while EGFR sensitizing mutations are found in approximately 
10% of North American and European NSCLC patients, the 
frequency has been reported to be as high as 50% to 60% in 
East Asia.6,7 On the other hand, the frequency of EGFR muta-
tions in subsets of populations has been less extensively stud-
ied, particularly in African Americans (AAs).
AAs have a higher incidence of lung cancer and tend 
to have poorer outcomes,8 emphasizing the importance to 
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confirm targets for therapy in this high-risk population. Prior 
smaller studies have found discrepant frequencies of EGFR 
mutations in this group, ranging from 2% to 19%.9–15 In a 
recent publication by Bollig-Fischer et al.,16 EGFR exon 
19 deletions were only detected in females, with a trend 
toward higher frequency in samples derived from AAs than 
from Caucasians. In addition, the authors observed a lower 
frequency of overall mutations among AAs compared with 
Caucasians, although important alterations like ALK rear-
rangements were not assessed.16
In this article, we describe the mutational spectrum of 
NSCLC in a pooled data set from AA patients, combining mul-
tiplex sequencing strategies and ALK testing. Our hypothesis 
was that NSCLC diagnosed in AAs has a different mutational 
profile than NSCLC diagnosed in Caucasians in North America.
PATIENTS AND METHODS
Patient Selection
Self-reported AA patients diagnosed with any stage 
NSCLC between 1988 and 2011 were retrospectively identi-
fied from three sites in Tennessee, Vanderbilt-Ingram Cancer 
Center (64 patients), Nashville General Hospital at Meharry 
Medical College (41 patients), and West Tennessee Healthcare 
(27 patients); one site in Michigan, Karmanos Cancer 
Institute, Wayne State University (29 patients); and one site 
in Ohio, Ohio State University (99 patients). Twenty samples 
from Wayne State overlap with the prior publication by Bollig-
Fischer et al.16 The patient search was based on tissue avail-
ability, and the clinical data correspond to available data from 
routine care delivered and documented in the medical records 
at each institution. Clinical characteristics were annotated, 
and tumor samples were evaluated for known recurrent driver 
mutations. For comparison purposes, histological subtypes 
were classified as either squamous (pure squamous cell carci-
noma) or nonsquamous (including all other subtypes). Study 
data were managed using REDCap electronic data capture 
tools hosted at Vanderbilt. To compare the data of AA patient 
with that of Caucasians diagnosed with NSCLC, we analyzed 
the lung adenocarcinoma17 and lung squamous cell carci-
noma18 data sets from The Cancer Genome Atlas (TCGA).19 
Clinical and mutational data from TCGA were downloaded 
from the publicly available repository and filtered to exclu-
sively include cases reported as “White.” Data were then 
obtained from this cohort for the same driver mutations tested 
in the panel used in this work, as described below. The institu-
tional review board at each participating center approved this 
project and waived the need for informed consent.
Tumor Genotyping
After routine pathology review, unstained slides were 
cut from formalin-fixed paraffin-embedded tissues and 
used for DNA extraction and sequencing. Classic driver 
mutations in EGFR, KRAS, BRAF, NRAS, AKT1, PIK3CA, 
PTEN, ERBB2, and MEK1 were evaluated by either 
SNaPshot/sizing assays in 161 patients (sites in TN and 
MI) or by next generation sequencing (NGS) in 99 samples 
(site in OH). SNaPshot/sizing assays were performed in a 
Clinical Laboratory Improvement Amendments-certified 
laboratory (Vanderbilt-Ingram Cancer Center) and fol-
lowed standard protocols for sample selection and genotyp-
ing.20 SNaPshot technique involved multiplex polymerase 
chain reaction, single-base extension, and analysis by 
capillary electrophoresis.20 Sizing assays were performed 
using established protocol to detect EGFR exon 19 dele-
tions, EGFR exon 20 insertions, and HER2 exon 20 inser-
tions.20,21 The NGS platform consisted of targeted gene 
sequencing using a NSCLC-specific panel, performed 
at Ohio State University. Libraries were constructed 
using the Agilent Haloplex kit (Agilent Technologies, 
Santa Clara, CA) and sequenced on an Illumina HiSeq 
2500 (Illumina, San Diego, CA). To enable a combined 
analysis with SNaPshot, NGS results were filtered to 
exclusively include the same base substitutions and inser-
tions/deletions covered by that panel, as summarized in 
Supplemental Table 1 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A866). The mutations evaluated 
herein have been characteristically defined as somatic 
events in NSCLC. Because no paired normal tissue was 
used, these mutations were considered to be somatic. More 
NGS methodological details and sequencing metrics are 
provided in Supplemental Methods (Supplemental Digital 
Content 2, http://links.lww.com/JTO/A867). ALK translo-
cations were evaluated in nonsquamous tumors (whenever 
adequate tissue was available after NGS/SNaPshot), using 
the Vysis ALK break apart fluorescence in situ hybridiza-
tion (FISH) probe kit (Abbott, Abbott Park, IL).22
Statistical Methods
Fisher’s exact test was used to compare the proportion 
of mutations between the two ethnic groups or between any 
two subgroups defined by clinical characteristics such as 
gender, smoking status, stage, and histology. Wilcoxon rank 
sum test was used to compare median age between any two 
ethnic (Caucasian versus AA) or mutant groups (mutant ver-
sus wild type). In multivariate analysis, logistic linear regres-
sion models were performed to adjust the mutation rate of 
KRAS/EGFR/Any driver for all other covariates mentioned 
above. To minimize the selection bias due to confounding 
clinical covariates, propensity score matching was performed 
on AAs and Caucasians by the optimal method, and the pro-
pensity score was obtained from the logistic regression of the 
binary response of AA or Caucasian on five covariates: age, 
gender, smoking, stage, and histology. The KRAS/EGFR/Any 
driver mutation rate was compared between the two matched 
ethnic groups. Survival curves were estimated using the 
Kaplan–Meier method and compared according to clinical 
covariates and molecular markers using log-rank test and Cox 
proportional hazards model (for hazard ratio estimate). P val-
ues of less than or equal to 0.05 were considered statistically 
significant. Given the exploratory nature of the current study, 
p values were not adjusted for multiple testing. Statistical 
analyses were performed using the statistical software R ver-
sion 3.0.1 (R Foundation for Statistical Computing, Vienna, 
Austria), SAS 9.3 (SAS, Cary, NC), and IBM SPSS version 
22.0 (IBM, Armonk, NY).
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RESULTS
Patient Characteristics
Two hundred sixty NSCLC cases resected from AAs 
were identified (Table 1). The median age was 60 (range, 35–
85) years, and 62.3% were males. Most of the patients were 
current smokers (63.5%), 23.1% were former smokers, and 
9.6% had never smoked. Eighty-one samples (31.2%) were 
squamous cell carcinomas, whereas 179 (68.8%) were clas-
sified as nonsquamous. Forty percent of the cases were diag-
nosed in advanced stages (III, 15.8%; IV, 23.8%).
Genotyping Results
Forty cases (15.4%) had KRAS mutations, 13 cases 
(5.0%) had EGFR mutations, and 2 (0.8%) were mutated in 
PIK3CA, whereas mutations in BRAF, NRAS, ERBB2, and 
AKT1 were found in one case each (0.4%). ALK FISH testing 
was performed in 115 nonsquamous tumors, with two positive 
results (1.7%) for fusions. Altogether, 61 cases (23.5%) har-
bored a classic driver alteration, and no overlap was observed 
among major drivers. Among 179 nonsquamous samples, 54 
(30.2%) presented a driver alteration. These results are sum-
marized in Figures 1 and 2.
The characteristics of patients and tumors that harbored 
classic mutations are summarized in Table 2, Supplemental 
Tables 2 to 4 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A866), and Supplemental Figure 1 (Supplemental 
Digital Content 3, http://links.lww.com/JTO/A868). EGFR 
alterations comprised exon 19 deletions in eight cases (61%), 
an exon 21 L858R point mutation in four cases (31%), and an 
exon 18 G719A in one case (8%). All EGFR mutant tumors 
were nonsquamous (p = 0.011), with higher prevalence in 
never smokers (p = 0.001 and 0.007 in comparison with cur-
rent and former smokers, respectively). The frequency of 
EGFR mutations was not associated with gender (p = 0.382), 
and all exon 19 deletions were described in males. KRAS 
mutations were detected in exons 2 and 3, corresponding to 
known variants in codons 12, 13, and 61. KRAS mutations 
were more common in nonsquamous subtypes (p = 0.001), 
current and former smokers (p = 0.134 and 0.271, respec-
tively, in comparison with never smokers), and KRAS-mutant 
cases had lower median age (p = 0.031) in comparison with 
wild type cases. ALK translocations were detected in nonsqua-
mous tumors from a current smoker (male, 42 years old) and 
a never smoker (female, 55 years old). Other mutations were 
less frequent, with BRAF and ERBB2 occurring only in non-
squamous tumors, AKT1 and NRAS in squamous tumors, and 
PIK3CA in both. Importantly, no difference was found accord-
ing to the sequencing technology used, i.e., SNaPshot or NGS. 
Taking the driver alterations altogether, the frequency of AA 
samples without a known driver was higher in squamous 
(p = 0.001) and slightly higher in stage I (p = 0.058).
Comparison with Caucasians
To compare the frequency of driver mutations in AAs, 
we identified 283 NSCLC cases resected from Caucasians 
in a search in TCGA. This group was slightly older (median 
ages, 67 versus 60 years, p < 0.001), more often female (48.8% 
TABLE 1.  Baseline Characteristics (N = 260)
Characteristic Frequency
Median age (range) 60 (35–85)
Gender, n (%)
  Male 162 (62.3)
  Female 96 (36.9)
  Unknown 2 (0.8)
Smoking status, n (%)
  Current smoker 165 (63.5)
  Former smoker 60 (23.1)
  Never smoker 25 (9.6)
  Unknown 10 (3.8)
Histology, n (%)
  Adenocarcinoma 137 (52.7)
  Squamous cell carcinoma 81 (31.2)
  NSCLC, NOS 27 (10.4)
  Others 15 (5.7)
Stage, n (%)
  I 114 (43.8)
  II 33 (12.7)
  III 41 (15.8)
  IV 62 (23.8)
  Unknown 10 (3.8)
NSCLC, non–small-cell lung cancer; NOS, not otherwise specified.
FIGURE 1.  Classic mutations in non–small-cell lung cancer (NSCLC) and nonsquamous tumors resected from African Americans.
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versus 37.2%, p = 0.007), and had less advanced stage disease 
(III/IV; 19.1% versus 41.2%, p < 0.001) than our cohort of AAs. 
Other baseline characteristics were balanced between these 
groups, including histology (p = 0.059) and smoking status 
(p = 1.00; Table 3). In a direct comparison, the frequencies of 
any KRAS (15.4% versus 18.0%, p = 0.423) and EGFR (5.0% 
versus 6.0%, p = 0.708) mutation were not different between 
AAs and Caucasians, respectively. Neither was the frequency 
of specific mutations in the genes such as EGFR exon 19 dele-
tions (p = 0.591; Supplemental Table 5, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A866). However, the fre-
quency of any driver mutation was significantly higher among 
Caucasians (31.8% versus 23.5%, p = 0.035). In a multivariate 
analysis combining these two data sets, smoking status and his-
tology were the only factors significantly associated with KRAS 
and EGFR status, although ethnicity was confirmed as an inde-
pendent factor associated with any driver mutation, along with 
histology (Supplemental Table 6, Supplemental Digital Content 
1, http://links.lww.com/JTO/A866). To verify these findings, we 
used a matching technique accounting for baseline variables. 
The frequency of any driver was consistently lower in AAs, 
whereas EGFR and KRAS were not statistically significant 
(Supplemental Table 7, Supplemental Digital Content 1, http://
links.lww.com/JTO/A866).
FIGURE 2.  Distribution of classic driver mutations in African Americans, with a significant pattern of mutual exclusivity.
TABLE 2.  Distribution and Characteristics of Specific Driver Alterations (N = 61)
Gene Exon Mutation N (%) SQ/Non-SQ Male/Female
Current/Former/ 
Never smoker
EGFR 19 Deletion 8 (3.1) 0/8 8/0 2/1/5
21 L858R 4 (1.5) 0/4 2/2 2/1/1
18 G719A 1 (0.4) 0/1 0/1 1/0/0
KRAS 2 G12C 19 (7.3) 0/19 10/9 14/2/1
2 G12S 2 (0.8) 1/1 1/1 1/1/0
2 G12V 10 (3.8) 3/7 6/4 6/3/0
2 G12A 3 (1.2) 0/3 2/1 1/2/0
2 G12D 2 (0.8) 0/2 1/1 2/0/0
2 G13C 3 (1.2) 0/3 2/0 3/0/0
3 Q61R 1 (0.4) 0/1 1/0 1/0/0
PIK3CA 9 E542K 1 (0.4) 1/0 1/0 0/0/1
20 H1047R 1 (0.4) 0/1 1/0 1/0/0
BRAF 15 V600E 1 (0.4) 0/1 1/0 1/0/0
NRAS 2 Q61L 1 (0.4) 1/0 0/1 1/0/0
ERBB2 20 Insertion 1 (0.4) 0/1 1/0 0/1/0
AKT1 3 E17K 1 (0.4) 1/0 1/0 1/0/0
ALK — Fusion 2 (1.7)a 0/2 1/1 1/0/1
aALK fusions were tested exclusively in nonsquamous samples.
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; SQ, squamous cell carcinoma.
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Survival Analysis
Within our cohort of AA patients, overall survival 
(OS) was higher among patients whose tumors harbored 
an EGFR mutation (p = 0.067). Conversely, no difference 
was noted according to KRAS (p = 0.401) or any mutation 
(p = 0.487). Patients who never smoked had significantly lon-
ger OS than current smokers (p = 0.015), and patients diag-
nosed at early stages (stages I and III) had significantly longer 
OS (p = 0.001 and 0.002, respectively) than those at stage IV. 
In contrast, histology (p = 0.639), gender (p = 0.673), and age 
(p = 0.426) had insignificant influence on survival. The sur-
vival curves and data are represented in Supplemental Figure 
2 (Supplemental Digital Content 3, http://links.lww.com/
JTO/A868) and Supplemental Table 8 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A866), respectively.
DISCUSSION
The current analysis of a pooled data set of clinically 
annotated NSCLC samples from AAs genotyped for frequent 
driver alterations provides important insights into the pro-
file of somatic mutations in this group. The use of multiplex 
sequencing technologies—in addition to FISH—enabled the 
simultaneous testing of multiple targetable oncogenes with 
immediate relevance for therapy decision. Our study confirms 
relevant findings and clears up previously described discrep-
ant results, while adding new insight into areas with a paucity 
of knowledge like the frequency of ALK fusions in AAs.
Our data suggest that the frequency of EGFR and 
KRAS mutations in AAs is not distinct from that of NSCLC 
in Caucasians. In this regard, discrepant results have been 
reported in the literature, especially concerning sensitizing 
mutations in EGFR.9–15 As summarized in Table 4, numer-
ous factors may have impacted previous results, including 
known variables such as the percentage of females, never 
smokers, and nonsquamous histology in each of the prior 
studies. These factors are highly associated with the preva-
lence of EGFR mutations and are likely responsible for some 
of the reported variances. For instance, Reinersman et al.14 
documented a 19% frequency of EGFR mutations among 
121 lung adenocarcinomas from AAs, which is higher than 
in our study (7.3% in 179 nonsquamous samples or 6.8% in 
117 adenocarcinomas). However, the lack of detailed clini-
cal data in their article precludes a more accurate compari-
son, because results could have been biased by a selective 
referral of patients with a higher pretest probability for muta-
tions. Likewise, similar results have been reported in other 
data sets that were not selected by race, such as in the Lung 
Cancer Mutation Consortium,1 which reported a 17% fre-
quency of EGFR mutations. However, Lung Cancer Mutation 
Consortium had a clear enrichment for females (60%), never 
smokers (34%), and adenocarcinomas (100%). In our study, 
two participating sites were community hospitals (Nashville 
General Hospital at Meharry Medical College and West 
Tennessee Healthcare). These sites contributed to form a 
cohort of patients more indicative of national norms, as 
opposed to many cohorts from academic centers, which may 
have been biased by selective referral. For instance, our data 
indicate a preponderance of NSCLC in males (male/female 
ratio of 1.7). This value is consistent with national trends,23 
where estimated annual incidence of lung cancer in 2015 was 
95.4 and 51.7 new cases per 100,000 AA male and female 
populations, respectively (ratio of 1.8).
The influence of clinical factors in the frequency of 
EGFR mutations in AAs is also observed in the study by Cote 
et al.10 Among 67 AAs genotyped for EGFR, eight samples 
(11.9%) harbored classic EGFR mutations, again a relatively 
higher rate than that described in this article. Nevertheless, as 
noted by other authors,24 seven mutant cases came from 11 
never smokers tested in that study (63.6%), whereas only 1 out 
of 56 (1.8%) ever smokers had an EGFR mutation. The ele-
vated prevalence of EGFR mutations was therefore driven by 
a very limited number of never smokers, vulnerable to biases. 
In our study, we have detected six EGFR mutations among 25 
never smokers (24.0%), which is the highest number of never 
smokers reported in AAs to date. Of note, this number com-
pares favorably with that found in Caucasians never smokers 
in TCGA (5 of 26, 19.2%).17 To specifically address the issue 
of potential imbalances in baseline characteristics, we have 
applied statistical techniques including multivariate analysis 
and propensity score matching. The absence of statistical sig-
nificance in the comparison of EGFR and KRAS mutations 
TABLE 3.  Comparison of Clinical/Tumor Characteristics 
Between the African American Cohort and Caucasian Patients 
from TCGA
Characteristics
African  
Americans 
(N=260)
Caucasians 
(N=283) P value
Clinical characteristics
  Median age (range) 60 (35–85) 67 (40–86) <0.001
  Gender, n (%) 0.007
   Male 162 (62.8) 145 (51.2)
   Female 96 (37.2) 138 (48.8)
  Histology, n (%) 0.059
   Squamous 81 (31.2) 111 (39.2)
   Nonsquamous 179 (68.8) 172 (60.8)
  Stage, n (%) <0.001
   I and II 147 (58.8) 229 (80.9)
   III and IV 103 (41.2) 54 (19.1)
  Smoking status, n (%) 1.00
   Current/former 225 (90.0) 244 (90.4)
   Never 25 (10.0) 26 (9.6)
Sequencing results
  KRAS status, n (%) 0.423
   Mutant 40 (15.4) 51 (18.0)
   Wild type 220 (84.6) 232 (82.0)
  EGFR status, n (%) 0.708
   Mutant 13 (5.0) 17 (6.0)
   Wild type 247 (95.0) 266 (94.0)
  Driver mutations, n (%) 0.035
   Any driver 61 (23.5) 90 (31.8)
   Unknown driver 199 (76.5) 193 (68.2)
TCGA, The Cancer Genome Atlas; EGFR, epidermal growth factor receptor.
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between AAs and Caucasians was consistent across all these 
models.
As opposed to data reported by Bollig-Fischer et al.,16 
most EGFR mutations described here came from males, and 
the frequency of exon 19 deletions was not distinct between 
AAs and Caucasians. These results highlight the importance 
of using large data sets to confirm preliminary findings in 
population studies. On the other hand, in line with previous 
data, the frequency of tumors harboring any driver altera-
tion in this combined cohort of AA patients was signifi-
cantly lower than that reported in Caucasians (23.5% versus 
31.8%, respectively; p = 0.035). In this regard, it should be 
noted that a reasonable number of samples was necessary to 
demonstrate a statistical difference in this comparison. For 
instance, although a numerical difference in any mutation 
rate between AAs and Caucasians is seen in a subset of 99 
samples from Ohio, this difference did not reach statistical 
significance because of the relatively low sample size in a 
separate data set (32% versus 24%; p = 0.163). Like in pre-
vious analyses described above, the lower frequency of any 
driver mutation in AAs was confirmed using different sta-
tistical models. It is also noticeable that the lower frequency 
was mostly driven by the non-EGFR, non-KRAS altera-
tions, where the most prominent difference was observed 
(3.1% versus 7.8% in AAs and Caucasians, respectively; 
p = 0.025).
Among the non-EGFR, non-KRAS alterations, we were 
able to assess ALK translocations in 115 nonsquamous sam-
ples, two of which were positive (1.7%). This rate is in the 
lower boundary of often reported frequencies of EML4–ALK 
in NSCLC, ranging from 2% to 7% in unselected popula-
tions.22,25 Although ALK fusions have not been reported in 
other AA mutational profiling studies, Gadgeel et al.26 pre-
sented a similar frequency (2.3%) for ALK protein expression 
among 260 AA NSCLC cases using immunohistochemistry. 
Ultimately, the limited number of drivers detected here under-
scores the need to evaluate a broader spectrum of alterations 
in this group, possibly spanning targetable copy number alter-
ations and other fusion genes. In this setting, a deeper analysis 
of noncanonical alterations assessed by NGS in AA popula-
tions could be very productive. It is important to note that 
TCGA data were filtered to include only the most clinically 
relevant driver mutations tested herein.
AAs have a unique inherited genomic landscape, with 
significant contributions from both African and European 
ancestors.27 Our data indicate that AA ethnicity is an inde-
pendent factor associated with a distinct pattern of driver 
mutations, which points toward a role for genetics. However, 
differences in life style, environmental exposures, and access 
to health care represent additional confounding factors that 
might explain lung cancer development and outcomes in AAs. 
Future studies will be necessary to better explore the risk fac-
tors—including the study of germ line variants—that could be 
related to the development of somatic mutations in patients 
with NSCLC.
In summary, we demonstrated a low prevalence of 
known somatic mutations in NSCLC from AA patients 
when compared with Caucasians. These data suggest that 
the majority of driver alterations in this group are yet to be 
described and therefore will require a more comprehensive 
assessment. Nonetheless, the occurrence of EGFR and KRAS 
mutations was not significantly different from that reported in 
Caucasians, and the frequency of ALK translocations was sim-
ilar to the lower boundary of the rates reported in unselected 
populations. There is a need to further explore targets for ther-
apy in AAs, using more comprehensive panels and assessing 
noncanonical alterations.
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